Gossamer Bio Faces Securities Class Action Risk
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 6 days ago
0mins
Should l Buy GOSS?
Source: Globenewswire
- Stock Price Collapse: Gossamer Bio's shares plummeted over 80%, dropping $1.71 to $0.42 after revealing that its Phase 3 PROSERA study failed to meet its primary endpoint, which directly undermined investor confidence and triggered a class action lawsuit.
- Inadequate Risk Disclosures: Throughout the period from June 16, 2025, to February 20, 2026, Gossamer's announcements failed to adequately warn investors about specific risks related to patient selection in Latin American clinical trials, leading to a misjudgment of the company's prospects.
- Legal Allegations: The lawsuit alleges that Gossamer omitted critical information regarding significant deviations in patient characteristics at Latin American sites, which could lead to an outsized placebo response, highlighting severe deficiencies in the company's transparency.
- Investor Action Recommendations: Affected investors are advised to gather brokerage records and contact Levi & Korsinsky for a no-obligation evaluation to assess eligibility for claims before the lead plaintiff deadline of June 1, 2026.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy GOSS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on GOSS
Wall Street analysts forecast GOSS stock price to rise
4 Analyst Rating
3 Buy
1 Hold
0 Sell
Strong Buy
Current: 0.344
Low
10.00
Averages
12.33
High
15.00
Current: 0.344
Low
10.00
Averages
12.33
High
15.00
About GOSS
Gossamer Bio, Inc. is a late-stage, clinical biopharmaceutical company, which is focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease (PH-ILD). Seralutinib, also known as GB002, is an investigational inhaled, small-molecule, platelet-derived growth factor receptor (PDGFR), colony-stimulating factor 1 receptor (CSF1R), and c-KIT inhibitor, being evaluated in a Phase III clinical trial for the treatment of PAH. Seralutinib is designed to target the mechanisms that underlie pulmonary hypertension and to be delivered to the site of disease, via dry powder inhaler. Seralutinib is being evaluated in a Phase III clinical trial for the treatment of pulmonary arterial hypertension (PAH). Inhaled seralutinib, which is designed to act on both isoforms of the PDGFR, α and β, as well as the CSF1R and c-KIT pathways.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Reminder for Gossamer Bio Securities Class Action
- Class Action Notice: Rosen Law Firm reminds investors who purchased Gossamer Bio securities between June 16, 2025, and February 20, 2026, that they must apply to be lead plaintiff by June 1, 2026, or risk losing their representation in the class action lawsuit.
- Fee Arrangement: Investors participating in the class action will incur no upfront costs, as the law firm operates on a contingency fee basis, which alleviates financial burdens and encourages more affected investors to join the lawsuit.
- Lawsuit Background: The lawsuit alleges that Gossamer Bio provided overly optimistic statements regarding its Phase 3 PROSERA study while concealing significant adverse facts about the study design, leading to investor losses when the truth emerged, potentially impacting the company's reputation and future financing capabilities.
- Law Firm's Strength: Rosen Law Firm is renowned for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, showcasing its expertise and resource advantages in handling such cases, thereby enhancing investor confidence in their representation.
See More
Gossamer Bio Faces Class Action Lawsuit Over Trial Failures
- Lawsuit Background: Gossamer Bio, Inc. (NASDAQ: GOSS) is facing a securities class action lawsuit following its February 23, 2026 announcement that the PROSERA study failed to meet its primary endpoint, with the lawsuit covering the period from June 16, 2025, to February 20, 2026, highlighting significant investor dissatisfaction with the company's transparency.
- Stock Price Plunge: Following the trial results announcement, Gossamer's stock plummeted by 80%, which not only undermined investor confidence but also prompted investigations by shareholder rights firms like Hagens Berman, potentially impacting the company's future financing capabilities.
- Trial Design Issues: The lawsuit alleges that Gossamer misrepresented the design of the PROSERA trial, including patient recruitment and site monitoring, as management previously touted the drug as a potential first-in-class therapy, failing to disclose critical trial flaws.
- Nasdaq Compliance Risk: On April 9, 2026, Gossamer revealed that since February 24, 2026, it has not met the minimum bid price of $1 required for continued listing on the Nasdaq Global Select Market, raising concerns about delisting and exacerbating investor anxiety.
See More
Gossamer Bio Faces Class Action Lawsuit Reminder
- Class Action Reminder: The Schall Law Firm reminds investors of a class action lawsuit against Gossamer Bio for violations of §§10(b) and 20(a) of the Securities Exchange Act, concerning securities purchased between June 16, 2025, and February 20, 2026, with a deadline to contact the firm by June 1, 2026, for participation.
- False Statements Allegation: The complaint alleges that Gossamer concealed adverse facts regarding the design of its Phase 3 PROSERA study, particularly concerning controls for placebo response at certain testing sites, rendering the company's public statements false and materially misleading throughout the class period.
- Investor Losses: As the market learned the truth about Gossamer, investors suffered damages, indicating significant deficiencies in the company's disclosure practices that could impact future stock performance and investor confidence.
- Legal Consultation Opportunity: The Schall Law Firm offers free consultations and encourages affected shareholders to reach out to discuss their rights, demonstrating the firm's commitment to protecting investor interests and providing support for potential legal actions.
See More
Investor Class Action Lawsuit Reminder
- Gossamer Bio Lawsuit: Gossamer Bio (NASDAQ:GOSS) faces a class action lawsuit for the period from June 16, 2025, to February 20, 2026, due to failure to disclose critical patient data, resulting in its Phase 3 PROSERA study not meeting primary endpoints, with a lead plaintiff deadline of June 1, 2026.
- New Era Energy Issues: New Era Energy (NASDAQ:NUAI) is involved in a class action lawsuit for the period from November 6, 2024, to December 29, 2025, for overstating progress on its Texas data center project and engaging in fraudulent schemes, with a deadline for lead plaintiffs also set for June 1, 2026.
- Medpace Holdings Allegations: Medpace Holdings (NASDAQ:MEDP) is facing a class action lawsuit for the period from April 22, 2025, to February 9, 2026, due to misleading statements regarding its projected book-to-bill ratio, with a lead plaintiff deadline of June 5, 2026.
- Legal Consultation Advice: Investors who have suffered losses in these companies are encouraged to contact The Law Offices of Frank R. Cruz to understand their legal rights and remain vigilant regarding the class actions to ensure necessary actions are taken before the deadlines.
See More
Gossamer Bio Faces Securities Class Action Lawsuit
- Stock Price Collapse: Gossamer Bio's shares plummeted over 80% on February 23, 2026, falling from $2.13 to $0.42, primarily due to the failure of its Phase 3 PROSERA study to meet the primary endpoint, severely undermining investor confidence.
- Executive Accountability: CEO Faheem Hasnain is named as an individual defendant, with allegations that he concealed critical trial design risks in the company's SEC filings and public statements, potentially exposing investors to significant losses.
- Legal Framework: Under Section 20(a) of the Securities Exchange Act of 1934, Hasnain faces personal liability as a controlling person for failing to fulfill his responsibilities during the company's violations of Section 10(b) and Rule 10b-5, which could lead to legal repercussions.
- Investor Action: Investors must apply by June 1, 2026, to become lead plaintiffs to participate in potential recoveries, with no upfront costs required for participation, ensuring that investor rights are protected.
See More
Gossamer Bio Investors Class Action Reminder
- Lawsuit Deadline: Investors in Gossamer Bio must file a lead plaintiff motion by June 1, 2026, to participate in a class action lawsuit concerning securities purchased between June 16, 2025, and February 20, 2026, aimed at recovering losses from the stock price collapse.
- Stock Price Crash: On February 23, 2026, Gossamer disclosed that its Phase 3 PROSERA study failed to meet its primary endpoint, resulting in an 80.3% drop in stock price to $0.42 per share, significantly harming investors and highlighting critical failures in the company's clinical trial.
- False Statements Allegations: The class action lawsuit alleges that throughout the class period, the company made materially false and misleading statements and failed to disclose adverse facts about its business and prospects, particularly regarding the low-risk characteristics of patients at Latin American sites.
- Legal Implications: Investors who purchased Gossamer securities during the class period may face legal implications; they are advised to contact legal counsel for more information and to participate in the lawsuit to protect their rights.
See More
Reminder for Gossamer Bio Securities Class Action
- Class Action Notice: Rosen Law Firm reminds investors who purchased Gossamer Bio securities between June 16, 2025, and February 20, 2026, that they must apply to be lead plaintiff by June 1, 2026, or risk losing their representation in the class action lawsuit.
- Fee Arrangement: Investors participating in the class action will incur no upfront costs, as the law firm operates on a contingency fee basis, which alleviates financial burdens and encourages more affected investors to join the lawsuit.
- Lawsuit Background: The lawsuit alleges that Gossamer Bio provided overly optimistic statements regarding its Phase 3 PROSERA study while concealing significant adverse facts about the study design, leading to investor losses when the truth emerged, potentially impacting the company's reputation and future financing capabilities.
- Law Firm's Strength: Rosen Law Firm is renowned for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, showcasing its expertise and resource advantages in handling such cases, thereby enhancing investor confidence in their representation.
See More
Gossamer Bio Faces Class Action Lawsuit Over Trial Failures
- Lawsuit Background: Gossamer Bio, Inc. (NASDAQ: GOSS) is facing a securities class action lawsuit following its February 23, 2026 announcement that the PROSERA study failed to meet its primary endpoint, with the lawsuit covering the period from June 16, 2025, to February 20, 2026, highlighting significant investor dissatisfaction with the company's transparency.
- Stock Price Plunge: Following the trial results announcement, Gossamer's stock plummeted by 80%, which not only undermined investor confidence but also prompted investigations by shareholder rights firms like Hagens Berman, potentially impacting the company's future financing capabilities.
- Trial Design Issues: The lawsuit alleges that Gossamer misrepresented the design of the PROSERA trial, including patient recruitment and site monitoring, as management previously touted the drug as a potential first-in-class therapy, failing to disclose critical trial flaws.
- Nasdaq Compliance Risk: On April 9, 2026, Gossamer revealed that since February 24, 2026, it has not met the minimum bid price of $1 required for continued listing on the Nasdaq Global Select Market, raising concerns about delisting and exacerbating investor anxiety.
See More
Gossamer Bio Faces Class Action Lawsuit Reminder
- Class Action Reminder: The Schall Law Firm reminds investors of a class action lawsuit against Gossamer Bio for violations of §§10(b) and 20(a) of the Securities Exchange Act, concerning securities purchased between June 16, 2025, and February 20, 2026, with a deadline to contact the firm by June 1, 2026, for participation.
- False Statements Allegation: The complaint alleges that Gossamer concealed adverse facts regarding the design of its Phase 3 PROSERA study, particularly concerning controls for placebo response at certain testing sites, rendering the company's public statements false and materially misleading throughout the class period.
- Investor Losses: As the market learned the truth about Gossamer, investors suffered damages, indicating significant deficiencies in the company's disclosure practices that could impact future stock performance and investor confidence.
- Legal Consultation Opportunity: The Schall Law Firm offers free consultations and encourages affected shareholders to reach out to discuss their rights, demonstrating the firm's commitment to protecting investor interests and providing support for potential legal actions.
See More
Investor Class Action Lawsuit Reminder
- Gossamer Bio Lawsuit: Gossamer Bio (NASDAQ:GOSS) faces a class action lawsuit for the period from June 16, 2025, to February 20, 2026, due to failure to disclose critical patient data, resulting in its Phase 3 PROSERA study not meeting primary endpoints, with a lead plaintiff deadline of June 1, 2026.
- New Era Energy Issues: New Era Energy (NASDAQ:NUAI) is involved in a class action lawsuit for the period from November 6, 2024, to December 29, 2025, for overstating progress on its Texas data center project and engaging in fraudulent schemes, with a deadline for lead plaintiffs also set for June 1, 2026.
- Medpace Holdings Allegations: Medpace Holdings (NASDAQ:MEDP) is facing a class action lawsuit for the period from April 22, 2025, to February 9, 2026, due to misleading statements regarding its projected book-to-bill ratio, with a lead plaintiff deadline of June 5, 2026.
- Legal Consultation Advice: Investors who have suffered losses in these companies are encouraged to contact The Law Offices of Frank R. Cruz to understand their legal rights and remain vigilant regarding the class actions to ensure necessary actions are taken before the deadlines.
See More
Gossamer Bio Faces Securities Class Action Lawsuit
- Stock Price Collapse: Gossamer Bio's shares plummeted over 80% on February 23, 2026, falling from $2.13 to $0.42, primarily due to the failure of its Phase 3 PROSERA study to meet the primary endpoint, severely undermining investor confidence.
- Executive Accountability: CEO Faheem Hasnain is named as an individual defendant, with allegations that he concealed critical trial design risks in the company's SEC filings and public statements, potentially exposing investors to significant losses.
- Legal Framework: Under Section 20(a) of the Securities Exchange Act of 1934, Hasnain faces personal liability as a controlling person for failing to fulfill his responsibilities during the company's violations of Section 10(b) and Rule 10b-5, which could lead to legal repercussions.
- Investor Action: Investors must apply by June 1, 2026, to become lead plaintiffs to participate in potential recoveries, with no upfront costs required for participation, ensuring that investor rights are protected.
See More
Gossamer Bio Investors Class Action Reminder
- Lawsuit Deadline: Investors in Gossamer Bio must file a lead plaintiff motion by June 1, 2026, to participate in a class action lawsuit concerning securities purchased between June 16, 2025, and February 20, 2026, aimed at recovering losses from the stock price collapse.
- Stock Price Crash: On February 23, 2026, Gossamer disclosed that its Phase 3 PROSERA study failed to meet its primary endpoint, resulting in an 80.3% drop in stock price to $0.42 per share, significantly harming investors and highlighting critical failures in the company's clinical trial.
- False Statements Allegations: The class action lawsuit alleges that throughout the class period, the company made materially false and misleading statements and failed to disclose adverse facts about its business and prospects, particularly regarding the low-risk characteristics of patients at Latin American sites.
- Legal Implications: Investors who purchased Gossamer securities during the class period may face legal implications; they are advised to contact legal counsel for more information and to participate in the lawsuit to protect their rights.
See More
